| Name | Title | Contact Details |
|---|
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body`s immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company`s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
Pharmathene, Inc is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Using artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, we are accelerating the discovery of proteins...